The one-month return of Illumina, Inc. (NASDAQ:ILMN) was -32.97%, and its shares lost 34.84% of their value over the last 52 weeks. On February 27, 2025, Illumina, Inc. (NASDAQ:ILMN) stock closed ...

It is best for small whole-genome sequencing, targeted gene sequencing, metagenomics, and CRISPR validation. The NextSeq 550 has been in use since 2018 and is great for mid-range projects such as ...

The Genomics Core offers a wide range of genomic and DNA/RNA services. We operate the Illumina NovaSeq X Plus, NextSeq 550, and MiSeq platforms for all Next Generation Sequencing and offer an ...

The system is fully compatible with Illumina’s NextSeq and NovaSeq sequencers, making high-resolution spatial research more cost-effective and accessible for single-cell and spatial researchers. To ...

while GSE128188 [GPL18573 Illumina NextSeq 500 (Homo sapiens)] includes 5 patients with sinus rhythm (SR) and 5 patients with AF. GSE2240 [GPL97 (HG-U133B) Affymetrix Human Genome U133B Array] ...

The spatial solution surpasses industry standards for scale and accuracy, and is compatible with Illumina NextSeq and NovaSeq sequencers, thereby materially reducing the cost of running large-scale ...

Illumina is raising the curtain on its upcoming ... The company said its spatial technology will run on its current NextSeq and NovaSeq hardware through a new multimodal software platform, with ...

The spatial solution surpasses industry standards for scale and accuracy, and is compatible with Illumina NextSeq and NovaSeq sequencers, thereby materially reducing the cost of running large ...

The spatial solution surpasses industry standards for scale and accuracy, and is compatible with Illumina NextSeq and NovaSeq sequencers, thereby materially reducing the cost of running large-scale ...

Nasdaq was shut on Feb 17 for Presidents Day. After notching a 52-week high of US$156.66 in November 2024, Illumina shares are now near its 52-week low of US$97.27. Follow the market’s reaction to ...